Role of renin blocker (Aliskiren) on Cisplatin induced-nephrotoxicity in rats

References

• Abdel-Daim, M.M., et al., 2019. The ameliorative effects of ceftriaxone and vitamin E against cisplatin-induced nephrotoxicity. Environmental science and pollution research, 26 (15), 15248–15254.
   PubMed Web of Science ®Google Scholar
• Abe, M., et al., 2013. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. Heart and vessels, 28 (4), 442–452.
   PubMed Web of Science ®Google Scholar
• Akca, G., et al., 2018. The protective effect of astaxanthin against cisplatin-induced nephrotoxicity in rats. Biomedicine & pharmacotherapy, 100, 575–582.
   PubMed Web of Science ®Google Scholar
• Al-Harbi, N.O., et al., 2015. Treatment with aliskiren ameliorates tacrolimus-induced nephrotoxicity in rats. Journal of the renin-angiotensin-aldosterone system, 16 (4), 1329–1336.
   PubMed Web of Science ®Google Scholar
• Alhoshani, A.R., et al., 2017. Protective effect of rutin supplementation against cisplatin-induced nephrotoxicity in rats. BMC nephrology, 18 (1), 194.
   PubMedGoogle Scholar
• Alshahrani, S., 2020. Aliskiren - a promising antioxidant agent beyond hypertension reduction. Chemico-biological interactions, 326, 109145.
   PubMed Web of Science ®Google Scholar
• Ashafaq, M., et al., 2016. Heavy metal-induced systemic dysfunction attenuated by tannic acid. The journal of environmental pathology, toxicology, and oncology, 35 (2), 109–120.
   PubMed Web of Science ®Google Scholar
• Baracho, N.C.D.V., et al., 2017. Urinary cytokine profiles according to the site of blockade of the renin-angiotensin system in nephrectomized rats. Jornal brasileiro de nefrologia: 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia, 39 (2), 108–118.
   PubMedGoogle Scholar
• Cetin, R., et al., 2006. Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. Journal of applied toxicology, 26 (1), 42–46.
   PubMed Web of Science ®Google Scholar
• Cherney, D.Z.I., et al., 2013. The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes. Diabetologia, 56 (10), 2308–2317.
   PubMed Web of Science ®Google Scholar
• Chirino, Y.I. and Pedraza-Chaverri, J., 2009. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 61 (3), 223–242.
   PubMed Web of Science ®Google Scholar
• Chtourou, Y., et al., 2015. Protective role of naringin against cisplatin induced oxidative stress, inflammatory response and apoptosis in rat striatum via suppressing ROS-mediated NF-κB and P53 signaling pathways. Chemico-biological interactions, 239, 76–86.
   PubMed Web of Science ®Google Scholar
• Coleman, J.J. and Cox, A.R., 2014. Antihypertensive drugs. Side effects of drugs annual, 35, 363–385.
   Google Scholar
• Cummings, B.S., Lasker, J.M., and Lash, L.H., 2000. Expression of glutathione-dependent enzymes and cytochrome P450s in freshly isolated and primary cultures of proximal tubular cells from human kidney. The journal of pharmacology and experimental therapeutics, 293 (2), 677–685.
   PubMed Web of Science ®Google Scholar
• Dasari, S. and Tchounwou, P.B., 2014. Cisplatin in cancer therapy: molecular mechanisms of action. European journal of pharmacology, 740, 364–378.
   PubMed Web of Science ®Google Scholar
• Feldman, D.L., et al., 2008. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension, 52 (1), 130–136.
   Google Scholar
• Galluzzi, L., et al., 2012. Molecular mechanisms of cisplatin resistance. Oncogene, 31 (15), 1869–1883.
   PubMed Web of Science ®Google Scholar
• Gross, O., et al., 2011. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. American journal of hypertension, 24 (3), 355–361.
   PubMed Web of Science ®Google Scholar
• Guo, S.X., et al., 2015. Astaxanthin attenuates early acute kidney injury following severe burns in rats by ameliorating oxidative stress and mitochondrial-related apoptosis. Marine drugs, 13 (4), 2105–2123.
   PubMed Web of Science ®Google Scholar
• Halici, Z., et al., 2016. Inhibiting renin angiotensin system in rate limiting step by aliskiren as a new approach for preventing indomethacin induced gastric ulcers. Chemico-biological interactions, 258, 266–275.
   PubMed Web of Science ®Google Scholar
• Hassan, H.A., et al., 2014. Amelioration of cisplatin-induced nephrotoxicity by grape seed extract and fish oil is mediated by lowering oxidative stress and DNA damage. Cytotechnology, 66 (3), 419–429.
   PubMed Web of Science ®Google Scholar
• Ibrahim, A., Eldaim, M.A., and Abdel-Daim, M.M., 2016. Nephroprotective effect of bee honey and royal jelly against subchronic cisplatin toxicity in rats. Cytotechnology, 68 (4), 1039–1048.
   PubMed Web of Science ®Google Scholar
• Jin, J., et al., 2015. Protective effect of wuzhi tablet (Schisandra Sphenanthera extract) against cisplatin-induced nephrotoxicity via Nrf2-mediated defense response. Phytomedicine: international journal of phytotherapy and phytopharmacology, 22 (5), 528–535.
   PubMed Web of Science ®Google Scholar
• Kamel, K.M., et al., 2014. Hesperidin and rutin, antioxidant citrus flavonoids, attenuate cisplatin-induced nephrotoxicity in rats. Journal of biochemical and molecular toxicology, 28 (7), 312–319.
   PubMed Web of Science ®Google Scholar
• Kedrah, A.E., et al., 2012. Effect of the direct renin inhibitor Aliskiren in the prevention of experimental contrast-induced nephropathy in the rat. Kidney and blood pressure research, 35 (6), 425–430.
   PubMed Web of Science ®Google Scholar
• Kim, Y.H., et al., 2006. Protective effect of the ethanol extract of the roots of Brassica rapa on cisplatin-induced nephrotoxicity in LLC-PK1 cells and rats. Biological & pharmaceutical bulletin, 29 (12), 2436–2441.
   PubMed Web of Science ®Google Scholar
• König, J., Müller, F., and Fromm, M.F., 2013. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacological reviews, 65 (3), 944–966.
   PubMed Web of Science ®Google Scholar
• Kumar, P., et al., 2017. TNF-α, IL-6 and IL-10 expressions, responsible for disparity in action of curcumin against cisplatin-induced nephrotoxicity in rats. Molecular and cellular biochemistry, 431 (1–2), 113–122.
   PubMed Web of Science ®Google Scholar
• Lebwohl, D., and Canetta, R., 1998. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. European journal of cancer, 34 (10), 1522–1534.
   PubMed Web of Science ®Google Scholar
• Lin, L., et al., 2015. Nephroprotective effect of gelsemine against cisplatin-induced toxicity is mediated via attenuation of oxidative stress. Cell biochemistry and biophysics, 71 (2), 535–541.
   PubMed Web of Science ®Google Scholar
• Liu, H. and Baliga, R., 2003. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney international, 63 (5), 1687–1696.
   PubMed Web of Science ®Google Scholar
• Liu, H., et al., 2016. Emodin ameliorates cisplatin-induced apoptosis of rat renal tubular cells in vitro by activating autophagy. Acta pharmacologica sinica, 37 (2), 235–245.
   PubMed Web of Science ®Google Scholar
• Lizakowski, S., Tylicki, L., and Rutkowski, B., 2013. Direct renin inhibition-a promising strategy for renal protection? Medical science monitor: international medical journal of experimental and clinical research, 19, 451–457.
   PubMed Web of Science ®Google Scholar
• Lowry, O.H., et al., 1951. Protein measurement with the Folin phenol reagent. The journal of biological chemistry, 193 (1), 265–275.
   PubMed Web of Science ®Google Scholar
• Luke, D.R., Vadiei, K., and Lopez-Berestein, G., 1992. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrology, dialysis and transplant, 7 (1), 1–7.
   PubMed Web of Science ®Google Scholar
• Ma, Z.N., et al., 2017. Supplementation of American ginseng berry extract mitigated cisplatin-evoked nephrotoxicity by suppressing ROS-mediated activation of MAPK and NF-κB signaling pathways. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 110, 62–73.
   PubMed Web of Science ®Google Scholar
• Maheshwari, R.A., et al., 2013. Amelioration of cisplatin-induced nephrotoxicity by statins. Indian journal of pharmacology, 45 (4), 354–358.
   PubMed Web of Science ®Google Scholar
• Mahfoz, A.M., et al., 2016. Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats. Naunyn-Schmiedeberg’s archives of pharmacology, 389 (12), 1315–1324.
   PubMed Web of Science ®Google Scholar
• Marie, H.H. and Prasad, D., 2003. Cisplatin nephrotoxicity: molecular mechanisms. Cancer therapy, 1, 47–61.
   PubMedGoogle Scholar
• Masanori, A., et al., 2012. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria. Hypertension research : official journal of the Japanese Society of Hypertension, 35 (8), 874–881.
   PubMed Web of Science ®Google Scholar
• Masuda, H., Tanaka, T., and Takahama, U., 1994. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochemical and biophysical research communications, 203 (2), 1175–1180.
   PubMed Web of Science ®Google Scholar
• Matavelli, L.C., Huang, J., and Siragy, H.M., 2012. Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. Journal of cardiovascular pharmacology, 59 (3), 281–287.
   PubMed Web of Science ®Google Scholar
• Meng, H., et al., 2017. Ameliorative effect of daidzein on cisplatin-induced nephrotoxicity in mice via modulation of inflammation, oxidative stress, and cell death. Oxidative medicine and cellular longevity, 2017, 1–10.
   Web of Science ®Google Scholar
• Mi, X.J., et al., 2018. The protective effects of maltol on cisplatin-induced nephrotoxicity through the AMPK-mediated PI3K/Akt and p53 signaling pathways. Scientific reports, 8 (1), 15922.
   PubMedGoogle Scholar
• Miller, R.P., et al., 2010. Mechanisms of cisplatin nephrotoxicity. Toxins, 2 (11), 2490–2518.
   PubMed Web of Science ®Google Scholar
• Mohmoodnia, L., et al., 2019. Protective effect of aliskiren against renal ischemia reperfusion via antioxidant property and nitric oxide signaling pathway. Immunopathologia Persa, 5 (1), e10–e10.
   Web of Science ®Google Scholar
• Moon, J.H., et al., 2013. Protective effects of 6-hydroxy-1-methylindole-3-acetonitrile on cisplatin-induced oxidative nephrotoxicity via Nrf2 inactivation. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 62, 159–166.
   PubMed Web of Science ®Google Scholar
• Mostafa, R.E., Saleh, D.O., and Mansour, D.F., 2018. Cisplatin-induced nephrotoxicity in rats: modulatory role of simvastatin and rosuvastatin against apoptosis and inflammation. Journal of applied pharmaceutical science, 8 (4), 43–50.
   Google Scholar
• Mukhopadhyay, P., et al., 2011. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free radical biology & medicine, 51 (9), 1774–1788.
   PubMed Web of Science ®Google Scholar
• Muller, D.N., et al., 2000. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension, 36 (2), 282–290.
   PubMed Web of Science ®Google Scholar
• Nussberger, J., et al., 2002. Angiotensin ii suppression in humans by the orally active renin inhibitor aliskiren (spp100): comparison with enalapril. Hypertension, 39 (1), E1–E8.
   PubMed Web of Science ®Google Scholar
• Ogawa, S., et al., 2011. Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy. Hypertension research: official journal of the Japanese Society of Hypertension, 34 (3), 400–401.
   PubMed Web of Science ®Google Scholar
• Oh, C.J., et al., 2017. Pyruvate dehydrogenase kinase 4 deficiency attenuates cisplatin-induced acute kidney injury. Kidney international, 91 (4), 880–895.
   PubMed Web of Science ®Google Scholar
• Ojha, S., et al., 2016. Plant-derived agents for counteracting cisplatin induced nephrotoxicity. Oxidative medicine and cellular longevity, 2016, 4320327–4320374.
   Web of Science ®Google Scholar
• Ozkok, A., and Edelstein, C.L., 2014. Pathophysiology of cisplatin induced acute kidney injury. BioMed research international, 2014, 967817–967826.
   Web of Science ®Google Scholar
• Pabla, N., and Dong, Z., 2008. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney international, 73 (9), 994–1007.
   PubMed Web of Science ®Google Scholar
• Palipoch, S., et al., 2014. Hepatoprotective effect of curcumin and alpha-tocopherol against cisplatin-induced oxidative stress. BMC complementary and alternative medicine, 14, 111.
   PubMed Web of Science ®Google Scholar
• Pan, H., et al., 2015. Mitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice. PLoS one, 10 (4), e0124775.
   PubMed Web of Science ®Google Scholar
• Perše, M. and VeIeriT-Haler, C., 2018. Cisplatin-induced rodent model of kidney injury: characteristics and challenges. BioMed research international, 2018, 1462802–1462829.
   PubMed Web of Science ®Google Scholar
• Ramesh, G. and Reeves, W.B., 2002. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. The journal of clinical investigation, 110 (6), 835–842.
   PubMed Web of Science ®Google Scholar
• Ramesh, G. and Reeves, W.B., 2004. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney international, 65 (2), 490–498.
   PubMed Web of Science ®Google Scholar
• Ramesh, G., et al., 2007. Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice. American journal of physiology. Renal physiology, 293 (1), F325–332.
   PubMed Web of Science ®Google Scholar
• Rashikh, A., et al., 2012. Aliskiren alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury. Journal of the renin-angiotensin-aldosterone system, 14 (1), 14–22.
   PubMed Web of Science ®Google Scholar
• Roth, M., Obaidat, A., and Hagenbuch, B., 2012. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. British journal of pharmacology, 165 (5), 1260–1287.
   PubMed Web of Science ®Google Scholar
• Salvesen, G.S. and Abrams, J.M., 2004. Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene, 23 (16), 2774–2784.
   PubMed Web of Science ®Google Scholar
• Saral, S., et al., 2016. Protective role of Diospyros lotus on cisplatin-induced changes in sperm characteristics, testicular damage and oxidative stress in rats. Andrologia, 48 (3), 308–317.
   PubMed Web of Science ®Google Scholar
• Siddik, Z.H., 2003. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22 (47), 7265–7279.
   PubMed Web of Science ®Google Scholar
• Stevens, M., et al., 2000. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes, 49 (6), 1006–1015.
   PubMed Web of Science ®Google Scholar
• Strasser, A., O’Connor, L. and Dixit, V.M., 2000. Apoptosis signaling. Annual review of biochemistry, 69, 217–245.
   PubMed Web of Science ®Google Scholar
• Suchal, K., et al., 2017. Protective effect of mangiferin on myocardial ischemia-reperfusion injury in streptozotocin-induced diabetic rats: role of AGE-RAGE/MAPK pathways. Scientific reports, 7, 42027.
   PubMed Web of Science ®Google Scholar
• Topcu-Tarladacalisir, Y., Sapmaz-Metin, M. and Karaca, T., 2016. Curcumin counteracts cisplatin-induced nephrotoxicity by preventing renal tubular cell apoptosis. Renal failure, 38 (10), 1741–1748.
   PubMed Web of Science ®Google Scholar
• Townsend, D.M., et al., 2009. Role of glutathione S-transferase pi in cisplatin-induced nephrotoxicity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 63 (2), 79–85.
   PubMed Web of Science ®Google Scholar
• Utley, H.G., Bernheim, F., and Hochstein, P., 1967. Effect of sulfhydryl reagents on peroxidation in microsomes. Archives of biochemistry and biophysics, 118 (1), 29–32.
   Web of Science ®Google Scholar
• Verma, P.K., et al., 2016. Total antioxidant and oxidant status of plasma and renal tissue of cisplatin-induced nephrotoxic rats: protection by floral extracts of Calendula officinalis Lin. Renal failure, 38 (1), 142–150.
   PubMed Web of Science ®Google Scholar
• Volarevic, V., et al., 2019. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. Journal of biomedical science, 26 (1), 25.
   PubMed Web of Science ®Google Scholar
• Waldmeier, F., et al., 2007. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug metabolism and disposition: the biological fate of chemicals, 35 (8), 1418–1428.
   PubMed Web of Science ®Google Scholar
• Wang, W., et al., 2014. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy. Journal of the renin-angiotensin-aldosterone system, 15 (4), 384–395.
   PubMed Web of Science ®Google Scholar
• Wang, Z., et al., 2013. Protective effects of aliskiren on ischemia-reperfusion-induced renal injury in rats. European journal of pharmacology, 718 (1–3), 160–166.
   PubMed Web of Science ®Google Scholar
• Wiggins, K., and Kelly, D., 2009. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney international, 76 (1), 23–31.
   PubMed Web of Science ®Google Scholar
• Yao, X., et al., 2007. Cisplatin nephrotoxicity: a review. The American journal of the medical sciences, 334 (2), 115–124.
   PubMed Web of Science ®Google Scholar
• Zhang, J., et al., 2009. Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine. Toxicologic pathology, 37 (5), 629–643.
   PubMed Web of Science ®Google Scholar
• Zhu, X., et al., 2017. S-Allylmercaptocysteine attenuates cisplatin-induced nephrotoxicity through suppression of apoptosis, oxidative stress, and inflammation. Nutrients, 9 (2), 166.
   PubMed Web of Science ®Google Scholar
• Ziypak, T., et al., 2015. Renoprotective effect of aliskiren on renal ischemia/reperfusion injury in rats: electron microscopy and molecular study. Renal failure, 37 (2), 343–354.
   PubMed Web of Science ®Google Scholar
• Zou, X.J., Yang, L., and Yao, S.L., 2012. Endoplasmic reticulum stress and C/EBP homologous protein-induced Bax translocation are involved in angiotensin II induced apoptosis in cultured neonatal rat cardiomyocytes. Experimental biology and medicine, 237 (11), 1341–1349.
   Web of Science ®Google Scholar